Reason for request
									
										Renouvellement d'inscription et Réévaluation du SMR
									
									
								 	
												
									                            
								
									
										
											
 
 
  
   Maintien du remboursement dans les mêmes conditions.
   
 
										
										
									
									
								
						 		
						 		
						 			
									
										Clinical Benefit
									
									
										
											
											
												| Low | 
												
													
														
															Le service médical rendu par ORALAIR 300 IR et ORALAIR 100 IR & 300 IR, comprimé sublingual, reste faible dans l’indication de l’AMM.  
														
													 | 
												
											
										
									
									
								
								
								
						 
						 		
						 		
								
						 		
								
	                         
	                     
                 
				
				
    
	 
				
		
				
		
				
		
                
                
                
					
				
				
	
	
                   
					
				
                
                
                
	
                
             
         
     
	
        
  
			
		
	
	
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
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
M99UVMGMMxFnhgpQ